Brandywine Pharmaceuticals, LLC recalls Theophylline Extended-Release Tablets
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- What's wrong
- CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
- Products
-
- Theophylline Extended-Release Tablets
- Company
- Brandywine Pharmaceuticals, LLC
- Where it was sold
-
Nationwide within U.S
- Units affected
- 1,332 100-count bottles
- Status
- Ongoing
Recall Relay is not affiliated with or endorsed by FDA or any agency. Details here are copied from the FDA notice and may lag behind it; the official notice is always the final word.